Developer · Germany
Apurano Pharmaceuticals GmbH
Private pharmaceutical company based in Warngau, Bavaria, Germany, built around the patented PuranoTec bio-nanotechnology process that converts poorly soluble actives into aqueous nanodispersions (particles <250 nm) for sublingual spray delivery. Lead asset is AP707 (adezunap), a THC-based cannabis flower nanodispersion in Phase 3 for chronic pain; a second cannabinoid candidate, beleronap, is in earlier development for psychiatric illnesses. CannaXan GmbH, the affiliate that ran the Phase 1 program, merged into Apurano Pharmaceuticals GmbH on 2023-01-26.
1compound
1program
1indication
Phase 3lead asset
Pipeline (1)
- Neuropathic painPhase 3Unknown
Recent activity
- Jan 31, 2024Phase changeAP707·Neuropathic painPhase 3Date of the last update the sponsor made to any of the Phase 3 registry records. All six records subsequently lapsed into ClinicalTrials.gov 'Unknown' status (last known: Recruiting); the estimated primary completion of 2024-09-30 passed with no posted results and no press release found through 2026-08-31. Registry staleness, not a documented discontinuation - the company site still presents the Phase 3 program as current.source ↗
- Nov 2, 2023Phase changeAP707·Neuropathic painPhase 3Six Phase 3 neuropathic-pain trials (plus two in chronic back pain, outside this record) registered 2023-10-10 and started 2023-11-02, sponsored by Apurano Pharmaceuticals GmbH. Program went directly from a single-dose Phase 1 to Phase 3 - no Phase 2 is registered anywhere.source ↗
- Mar 2, 2022Phase changeAP707·Neuropathic painPhase 1SELECT-I (NCT05267769) started: single-dose pharmacokinetics and tolerability of AP707 in 12 healthy volunteers, sponsored by CannaXan GmbH (merged into Apurano Pharmaceuticals GmbH 2023-01-26). Completed 2022-04-03.source ↗
Competitive landscape
Other companies developing against Apurano Pharmaceuticals GmbH's targets or indications.